Oxford-Latinoamerican Initiative


Accelerating immuno-oncology research in Latinomerica

Prof Tim Elliott, Dr Camilo Quevedo and Dr Isabela Pedroza-Pacheco

Oxford Cancer
NDM Centre for Immuno-Oncology
Nuffield Department of Medicine
University of Oxford


CENTRE *for* IMMUNO-ONCOLOGY

1000 Oxford Cancer Researchers




OXFORD CANCER

Research Excellence


nature communications

Article

Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms


nature communications

Article

Multimodal cell-free DNA whole-genome TAPS is sensitive and reveals specific cancer signals


Received: 4 January 2024
Accepted: 5 December 2024
Published online: 08 January 2025


Explore content · About the journal · Publish with us

nature > nature communications > articles > article

Article | Open access | Published: 26 October 2024

Genomic landscape of adult testicular germ c tumours in the 100,000 Genomes Project


Explore content · About the journal · Publish with us

nature > nature communications > articles > article

Article | Open access | Published: 06 September 2024


Enhanced tumor response to adoptive T cell ther with PHD2/3-deficient CD8 T cells


Explore content · About the journal · Publish with us

nature > nature communications > articles > article

Article | Open access | Published: 29 April 2024

Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers


Explore content · About the journal · Publish with us

nature > nature communications > articles > article

Article | Open access | Published: 22 January 2024

MARS an improved de novo peptide candidate selection method for non-canonical antigen target discovery in cancer

Hanqing Liao, Carolina Barra, Zhicheng Zhou, Xu Peng, Isaac Woodhouse, Arun Tailor, Robert Parker, Alexia Carré, Persephone Borrow, Michael J. Hogan, Wayne Paes, Laurence C. Eisenlohr, Roberto Mallone, Morten Nielsen & Nicola Ternette

Article

The genomic landscape of 2,023 colorectal cancers

Cancer Cell

CellPress OPEN ACCESS

Article

Tracking *in situ* checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis

Tarun Gupta, Agne Antanaviciute, Chloe Hyun-Jung Lee, Rosana Ottakandathil Babu, Anna Aulicino

CellPress OPEN ACCESS

Cancer Cell

Article

Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma

Thomas M. Carroll, Joseph A. Chadwick, Richard P. Owen, Michael J. White, Joseph Kaplinsky, Iliana Peneva, Phil F. Xie, Jaeho Chang, Andrew Roth, Bob Amess, Sabrina A. James, Margarida Rei, Katy J. McCann, Ayo O. Omiyale, Brittany-Amber Jacobs, Simon R. Lord, Stewart Norris-Bulpitt, Lucinda Griffiths, Kristen Aufiero Ramirez, Toni Ricciardi, Mary J. Macri, Aileen Ryan, Benoit J. Van den Eynde, Ioannis Karydis, Benjamin Schuster-Böckler

5,278 papers in PubMed 2023-2025


Explore content · About the journal · Publish with us

nature > nature communications > articles > article

Article | Open access | Published: 10 March 2025

Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer

Esra Güç, Agatha Treveil, Emma Leach, Anna Broomfield, Antonio Camera, James Clubley, Paula Nieto Garcia, Anastasiya Kazachenka, Rahul Khanolkar, Luis del Carpio, Holger Heyn, Jessica C. Hassel, Joseph J. Sacco, Sarah Stanhope, Laura Collins, Josep M. Piulats, Koustubh Ranade & Adel Benlahrech

Explore content · About the journal · Publish with us

nature > nature communications > articles > article

Article | Open access | Published: 08 January 2025

Diet-wide analyses for risk of colorectal cancer: prospective study of 12,251 incident cases among 542,778 women in the UK

Keren Papier, Kathryn E. Bradbury, Angela Balkwill, Isobel Barnes, Karl Smith-Byrne, Marc J. Gunter, Sonja I. Berndt, Loic Le Marchand, Anna H. Wu, Ulrike Peters, Valerie Beral, Timothy J. Key & Gillian K. Reeves

Cell

A Polymorphic p53 Response Element in KIT Ligand Influences Cancer Risk and Has Undergone Natural Selection

Jorge Zeron-Medina, Xuting Wang, Emmanouela Repapi, Michelle R. Campbell, Dan Su, Francesc Castro-Giner, Benjamin Davies, Elisabeth F.P. Peterse, Natalia Sacilotto, Graeme J. Walker, Tamara Terzian, Ian P. Tomlinson, Neil F. Box, Nicolai Meinshausen, Sarah De Val, Douglas A. Bell, and Gareth L. Bond



Explore content · About the journal · Publish with us

nature > nature reviews immunology > journal clubs > article

Journal Club | Published: 08 January 2025

Preprint watch

In vivo enhancement of tumour-specific T cells via


Explore content · About the journal · Publish with us

nature > nature genetics > articles > article

Article | Open access | Published: 04 September 2023

Single-cell multi-omics identifies chronic inflammation as a driver of *TP53*-mutant leukemic evolution

Alba Rodriguez-Meira, Ruggiero Norfo, Sean Wen, Agathe L. Chédeville, Haseeb Rahman, Jennifer O'Sullivan, Guanlin Wang, Eleni Louka, Warren W. Kretzschmar, Aimee Paterson, Charlotte Brierley, Jean-Edouard Martin, Caroline Demeule, Matthew Bashton, Nikolaos Sousos, Daniela Moralli, Lamia Subha Meem, Joana Carrelha, Bishan Wu, Angela Hamblin, Helene Guermouche, Florence Pasquier, Christophe

Science Immunology

Current Issue · First release papers · Archive · About

RESEARCH ARTICLE | IMMUNOMETABOLISM

Asparagine availability controls germinal center B cell homeostasis

Explore content · About the journal · Publish with us

nature > nature reviews cancer > review articles > article

Review Article | Published: 29 January 2025

Cross-priming in cancer immunology and immunotherapy

Carlos Luri-Rey, Álvaro Teijeira, Stefanie K. Wculek, Carlos de Andrea, Claudia Herrero, Alvaro Lopez-Janeiro, María E. Rodríguez-Ruiz, Ignacio Heras, Maria Aggelakopoulou, Pedro Berraondo, David Sancho & Ignacio Melero


Explore content · About the journal · Publish with us

nature > nature communications > articles > article

Article | Open access | Published: 24 January 2024


Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity

Isaac Dean, Colin Y. C. Lee, Zewen K. Tuong, Zhi Li, Christopher A. Tibbitt, Claire Willis, Fabrina Gaspal, Bethany C. Kennedy, Veronika Matei-Rascu, Rémi Fiancette, Caroline Nordenvall, Ulrik Lindforss, Syed




By combining scientific expertise and infrastructure across Oxford our goal is to advance immunological discovery, enable earlier cancer detection, and improve outcomes for patients with cancer

A global effort for vaccines and therapeutics



Including Latinoamerica in our global efforts



Our vision

To harness Latinoamerica's exceptional biological and genetic diversity:

- to advance immunological discovery,
- strengthen national research capacity,
- enable earlier cancer detection,
- and improve outcomes for patients with cancer.

By combining scientific expertise, infrastructure, and AI, it aims to accelerate the development and equitable access to next-generation cancer vaccines and immune-based treatments, transforming cancer prevention, detection, and care.



CENTRE *for* IMMUNO-ONCOLOGY

December 2025







March 2026






May 2026



Pillars of the Collaboration



What do we need?

- Local and international support from various public and private stakeholders in Mexico and Brasil
- Engagement from University of Oxford
- Experience in setting up satellite labs in Mexico
- Experience in building capacity by engaging with local universities
- Identification of Latinoamerican facilites to support cancer vaccine development

- Support from Latinoamerican countries to contribute to pillar 1
- Coordinated financial support UK-LATAM
- Centralised programme for global health
- Infrastructure to build biobanks

Health Data Consortium

- **DECOD-LATAM**: Democratising Multi-omic Systems Immunology to Address Early-Onset Cancer in Brazil and Across Latin America (Pillar 1 Strategic Framework). Lead = Pedroza-Pacheco. With AC Camargo, INCA, Albert Einstein, IOC hospital, CNPEM. (**Pillar 1**).
- **BIO-BRAZIL-IM: BIO**prospecting **BRAZIL**ian compounds for **I**mmune **M**odulation. Lead = Galvez-Cancino with CNPEM.. (**Pillar 1**)
- **DEBIND-LATAM STRATEGIC FRAMEWORK: DE**-**BI**asing for improved bi**N**ding pre**D**iction in **Latin America**. Lead = Elliott, Lee. CNPEM with genomic data from AC Camargo and INCA. (**Pillar 1 and 2**)
- **PROTECT-EBV-BR: P**aediatric **R**esearch trial **O**n EBV-**t**arg**e**ted **C**ancer **T**herapy in Brazil. Lead = Leung with CT-Vacinas (UFMG) and Fiocruz (**Pillar 3 Strategic Framework)**
- **VECTOR-LATAM: V**accines for **E**pitope-based **C**ancer **T**argeting and **O**ncology **R**esearch in **Latin America.** Lead = Elliott, Lee, Leung with A.C. Camargo, INCA, CNPEM, Fiocruz, Albert Einstein. **(Pillar1, 2 and 3)**
  - Development of Next-Generation Viral and VLP-Based Cancer Vaccine Platforms
  - Development of Personalized Neoantigen mRNA Cancer Vaccines
- **BRAINS**: Brazilian AI Network for Science. Lead = Elliott, Lee with UFMG (pilot) widening to all partners